A Phase 2 interventional study of osilodrostat in Cushing's Syndrome, sponsored by RECORDATI GROUP. Completed at 56 sites in 21 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by RECORDATI GROUP · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Cushing Syndrome with a site in United States — 14 open to participants now, 17 under way, none of them phase 3. Cushing Syndrome · United States.
Among the 58 studies in Cushing Syndrome with a site in United States, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2018, is one of 17 in phase 2, and was the 36th registered.
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
Browse Cushing Syndrome studies →14 of the 58 studies in Cushing Syndrome with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
RECORDATI GROUP · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Sparrow Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 8 · Phase 4 3
First in 1982; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 44 across 58 interventional studies indexed under Cushing Syndrome.
Median enrollment 35 across the 34 interventional studies, 206 across the 23 observational. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 58 have an industry lead sponsor. The 10 most frequent:
RECORDATI GROUP is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
RECORDATI GROUP has 5 studies filed under Cushing Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Cushing Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03364803Memorial Sloan Kettering Cancer CenterCollecting Information About Treatment Results for Patients With Cushing's Syndrome | 2026-11-28 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07104812Mayo ClinicImpact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) | 2027-01 |
| NCT05382156RECORDATI GROUPNon-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome | 2027-06 |
| NCT03708900RECORDATI GROUPPharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | 2027-07-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 58 studies in Cushing Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.
There will be no screening period for this study. Eligible subjects can start their treatment with osilodrostat as soon as they are enrolled in the study. The first study visit will be scheduled at the time of the last study visit for the parent study. Subjects must return to the study center at least on a quarterly basis (every 12 weeks ± 2 weeks) for safety and clinical benefit assessments, and resupply of study medication. Drug dispensing and administration information and adverse events will be collected. The subject may return to the clinic at any given time as per standard of care or treating physician recommendation; however, only the quarterly study visits will be recorded in the Case Report Form (CRF). Study medication dispensed will be recorded in the CRF dose administration page.
All adverse events and serious adverse events, including pregnancy, will be collected throughout the study. Subjects will continue to be treated in this roll-over study until they are no longer benefiting from their osilodrostat treatment as judged by the Investigator or until osilodrostat is commercially available or until one of other discontinuation criteria is met.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and for 1 week of study after stopping medication. Highly effective contraception methods include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
open label, with patients receiving same dose as provided in the parent study
Drug: osilodrostat
osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
Also known as: LCI699
Number of Participants With Adverse/Serious Adverse Events
To evaluate long-term safety data with osilodrostat treatment (Frequency and severity of adverse events (AEs)/serious adverse events (SAEs))
Time frame: up to 5 years
Percentage of Patients With Clinical Benefit
Proportion of patients with clinical benefit as assessed by the Investigator at scheduled visits based on medical check-up and lab values such as Urine Free Cortisol.
Time frame: up to of 5 years
There was no screening period for the study, eligible patients were able to start study treatment as soon as they were enrolled. The study was conducted for 5 years from first patient first visit. Patients continued to be treated in this roll-over study until they no longer received clinical benefit from treatment with osilodrostat (as judged by the Investigator), until osilodrostat was commercially available in their country, or until one of the other discontinuation criteria were met.
| Milestone | Osilodrostat |
|---|---|
| Started | 127 |
| Completed | 99 |
| Not completed | 28 |
| Withdrew: Adverse event | 13 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Physician decision | 4 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Death | 1 |
| Withdrew: New therapy for study indication | 1 |
To evaluate long-term safety data with osilodrostat treatment (Frequency and severity of adverse events (AEs)/serious adverse events (SAEs))
| Participants | Osilodrostat |
|---|---|
| Adverse events (AEs) | 115 |
| Treatment-related AEs | 50 |
| Adverse events of CTCAE Grade ≥ 3 | 34 |
| Treatment-related AEs of CTCAE Grade ≥ 3 | 3 |
| Serious adverse events | 35 |
| Treatment-related SAEs | 4 |
| Fatal SAEs | 2 |
| Treatment-related fatal SAEs | 0 |
| Adverse events leading to discontinuation | 14 |
| Treatment-related AEs leading to discontinuation | 5 |
| Adverse events leading to dose interruption or adjustment | 56 |
| Treatment-related AEs leading to dose interruption or adjustment | 35 |
| Adverse events requiring additional therapy | 94 |
| Treatment-related AEs requiring additional therapy | 17 |
| Adverse events of special interest (AESIs) | 51 |
| Treatment-related AESIs | 29 |
Proportion of patients with clinical benefit as assessed by the Investigator at scheduled visits based on medical check-up and lab values such as Urine Free Cortisol.
| Participants | Osilodrostat |
|---|---|
| Week 1 | 127 |
| Week 12 | 122 |
| Week 24 | 119 |
| Week 36 | 114 |
| Week 48 | 103 |
| Week 96 | 74 |
| Week 144 | 52 |
| End of treatment | 99 |
Collected over From enrolment up to 30 days after the last administration of study treatment (up to 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Osilodrostat | 2/127 (1.6%) | 35/127 (27.6%) | 115/127 (90.6%) |
| Event | Osilodrostat |
|---|---|
| COVID-19Infections and infestations | 7/127 |
| CholelithiasisHepatobiliary disorders | 3/127 |
| Pitituary tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/127 |
| Adrenal insufficiencyEndocrine disorders | 2/127 |
| ACTH-producing pituitary tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/127 |
| Acute stress disorderPsychiatric disorders | 1/127 |
| Adenocarcinoma pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/127 |
| Alanine aminotransferase increasedInvestigations | 1/127 |
| AppendicitisInfections and infestations | 1/127 |
| Aspartate aminotransferase increasedInvestigations | 1/127 |
| Event | Osilodrostat |
|---|---|
| COVID-19Infections and infestations | 29/127 |
| Adrenal insufficiencyEndocrine disorders | 16/127 |
| HeadacheNervous system disorders | 16/127 |
| NauseaGastrointestinal disorders | 14/127 |
| DiarrhoeaGastrointestinal disorders | 13/127 |
| Cortisol free urine increasedInvestigations | 13/127 |
| SARs-Cov-2 test positiveInvestigations | 13/127 |
| NasopharyngitisInfections and infestations | 12/127 |
| HypertensionVascular disorders | 11/127 |
| InfluenzaInfections and infestations | 11/127 |
The starting dose of this roll-over study was the same as the one the patients were taking at the end of the parent studies. In addition, they underwent to dose adjustment according to the urine cortisol level and possible AEs. The daily dosage ranged from 1mg every 3 days to 30mg twice a day. So it is not feasible to report the results according to the drug dosage and data has been analysed as one arm.
| Age, Continuous(years) | Osilodrostat |
|---|---|
| Mean | 44.2 ± 12.39 |
| Age, Customized(Participants) | Osilodrostat |
|---|---|
| <65 years | 119 |
| ≥65 years | 8 |
| Sex: Female, Male(Participants) | Osilodrostat |
|---|---|
| Female | 95 |
| Male | 32 |
| Ethnicity (NIH/OMB)(Participants) | Osilodrostat |
|---|---|
| Hispanic or Latino | 14 |
| Not Hispanic or Latino | 94 |
| Unknown or Not Reported | 19 |
| Race (NIH/OMB)(Participants) | Osilodrostat |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 26 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 96 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Weight(kg) | Osilodrostat |
|---|---|
| Mean | 74.59 ± 21.253 |
| Height(cm) | Osilodrostat |
|---|---|
| Mean | 163.73 ± 9.839 |
| Body Mass Index(Kg/m^2) | Osilodrostat |
|---|---|
| Mean | 27.84 ± 7.631 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Oct 2018 to primary completion in Nov 2023, 61 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osilodrostat